when were glp 1 agonists discovered JCI Frontiers | GLP-1R in diabetes

doi:10.4254/wjh.v14.i1.45 15

There have been different clinical trials conducted on patients with obesity demonstrating the beneficial effect of exercise on metabolic risk factors and liver characteristics

This has made them a cornerstone in treating patients with Type 2 diabetes and chronic kidney disease

And more of these will hit the market in the next few years

The first GLP-1 injectable receptor agonist exenatide was approved by the U.S

This review addresses the promising landscape of GLP-1 RAs to treat persons with overweight or obesity, with or without T2DM, within the context of CKD, assessing their safety and impact on weight, metabolic control, blood pressure and kidney and cardiovascular outcomes, as part of a holistic patient-centred approach to preserve CKM health